This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

NewLink Genetics Appoints Mr. Brian Wiley As Vice President Of Business Development

AMES, Iowa, Jan. 3, 2013 /PRNewswire/ -- NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutic products to improve treatment options for cancer patients, today announced the appointment of Mr. Brian Wiley as Vice President of Business Development.  In addition to business development responsibilities, Mr. Wiley will lead the commercialization strategy and pre-commercial activities for NewLink's HyperAcute® Pancreas Immunotherapy, algenpantucel-L.

"Brian brings extensive and varied pharmaceutical experience to our management team, most recently with key roles in both the sale of Gloucester Pharmaceuticals to Celgene Corporation and the purchase of Abraxis Health by Celgene," commented Dr. Charles Link, Chief Executive Officer of NewLink.  Dr. Link added, "In addition to his business development experience, Brian has had key responsibilities in the launch, marketing and sales of a variety of oncology products at both major pharmaceutical companies and smaller biotech companies.  We are excited to have Brian join our team."

Mr. Wiley has over 20 years of pharmaceutical experience, with 16 of those years in oncology markets.  He has had management responsibilities at Celgene Corporation, Gloucester Pharmaceuticals, Millennium Pharmaceuticals (currently Takeda) and Aventis Pharmaceuticals (currently Sanofi-Aventis).  Mr. Wiley has also served as an independent consultant to numerous companies in the oncology market.  His responsibilities have included business development, commercial strategy, marketing, reimbursement, national accounts, sales and sales management.

About algenpantucel-L

NewLink's algenpantucel-L is an "off-the-shelf" immunotherapy product candidate consisting of two allogeneic pancreatic cancer cell lines.  These cell lines were chosen to provide a broad coverage of pancreatic cancer antigens and were then modified to express alpha-gal on the cell surface to increase immunogenicity.  Each modified cell line is grown in large-scale culture, harvested, packaged and irradiated.  Approximately 150 million cells of each HyperAcute Pancreas cell line are given by intradermal injection with each treatment.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,976.31 +263.65 1.49%
S&P 500 2,086.24 +25.22 1.22%
NASDAQ 4,947.4410 +56.2220 1.15%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs